Updated time: 2020-07-08 21:07:41
Lung cancer in East Asia is characterized by high percentage of never-smokers, early-onset and predominant EGFR mutations. However, most patients developed resistance to EGFR-targeted therapy. In addition, patients with different EGFR mutation display distinct overall survival and cancer progression. To address unmet clinical needs, we designed a prospective study on non-small cell lung cancer patients. We collected the tumor and adjacent normal tissues from patients composed of mostly early stage and non-smoker in Taiwan and performed a deep proteomic and phosphoproteomic study on this cohort representing early stage non-smoking lung adenocarcinoma. We established an analytical pipeline and illuminated the molecular phenotype of this demographically distinct disease. We constructed a proteomics-informed novel classification system which utilize the proteomic subtyping to categorize the clinical early-stage patients into early stage and late-like patients. The proteomic subtyping distinguished the clinical characteristics of patient with different EGFR mutations, including aggressive features and survival.
- Our integrated proteomic pipeline achieves high sensitivity proteomic analysis, which is better than the standard set by National Cancer Institute (>10,000 proteins).
- High performance proteomic technique provides new molecule subtyping to identify patients with aggressive features and worse survival for clinical staging and selection of early cancer candidates and druggable targets.

Fig1. Proteome-informed classification adds a new layer of molecular resolution to distinguish the clinical characteristics of early stage lung adenocarcinoma patients.
03A-1090210
2020-06-12
patents pending
- Proteome-informed classification distinguish the clinical characteristics of early stage patients and improve the accuracy of clinical staging for patient stratification.
- Proteomic subtypes reveals the molecular remodeling associated with tumor progression in early stage lung adenocarcinomas, and highlights candidate protein biomarkers and druggable targets.
Yi-Ju Chen, Ya-Hsuan Chang, Sung-Liang Yu, Huei-Wen Chen, Jin-Shing Chen, Gee-Chen Chang, Pan-Chyr Yang, Hsuan-Yu Chen, Yu-Ju Chen, Jyoti S. Choudhary, Theodoros I. Roumeliotis
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Fig2. Integrative deep proteomic technique and bioinformatic package analysis for high-risk judgement of early lung adenocarcinoma patients.

Proteomic Subtyping for Early Stage Lung Adenocarcinoma